Back
Filter by:
  • Trial Status
  • Trial Phase
  • Age
  • Sex
  • Location

    location

    Clear All

About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

339,504 studies
in
214 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 05/30/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 05/30/2020.
Displaying: 530 trials in your specialties ()
View trials across your selected specialties

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
View Full Trial
INTERVENTION

Drug: siG12D-LODER, Drug: Gemcitabine+nab-Paclitaxel

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Rambam Medical Center, Haifa, Israel

Brief Summary

In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable locally advanced pancreatic cancer combined with chemotherapy treatment. Primary Outcome: - Progression-free survival (PFS) in the study population.

Induction Chemotherapy With ACF Followed by Chemoradiation Therapy for Adv. Head & Neck Cancer

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Head and Neck Neoplasms
View Full Trial
INTERVENTION

Drug: paclitaxel albumin-stabilized nanoparticle formulation, Drug: Cisplatin, Drug: Fluorouracil, Radiation: Intensity modulated radiation therapy, Drug: Cetuximab, Procedure: Quality-of-life assessment

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Washington University School of Medicine, Saint Louis, Missouri, United States

Brief Summary

This phase II trial studies the safety and effectiveness of an induction chemotherapy (ACF) consisting of paclitaxel albumin-stabilized nanoparticle formulation (nab-paclitaxel), cisplatin and fluorouracil followed by chemoradiation therapy in treating patients with stage III-IV squamous cell cancer of the head and neck. ACF may be an effective way to reduce or downgrade locally aggressive tumors, and improve the chance of eradication by chemoradiation.

Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  • Status
    Active, not recruiting
  • Phase
    Phase 2
  • Condition
    Head and Neck Cancer
View Full Trial
INTERVENTION

Drug: Cetuximab, Drug: Nab-paclitaxel, Drug: Carboplatin

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

Brief Summary

This is a non-randomized, open-label phase II trial of 40 patients with poor prognosis head and neck cancer, defined as surgically unresectable and/or ≥N2b disease and judged appropriate for non-surgical definitive therapy.

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Unresectable Gastric Cancer

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Gastric Cancer Stage
View Full Trial
INTERVENTION

Drug: sintilimab, Drug: apatinib, Drug: S1, Drug: Nab paclitaxel

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China

Brief Summary

This is a phase II study to evaluate the efficacy and safety of combination of sintilimab (PD-1 inhibitor) , apatinib and chemotherapy in unresectable advanced gastric cancer patients with oligo metastasis. This study was designed as single arm with fixed number of participants.

Split-course SBRT for Borderline Resectable and Locally Advanced Pancreatic Cancer

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Pancreatic Neoplasms
View Full Trial
INTERVENTION

Drug: nab-Paclitaxel+Gemcitabine, Radiation: split-course SBRT

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Fujian Medical University Union Hospital, Fuzhou, Fujian, China

Brief Summary

Exploratory assessment of the efficacy and safety of gemcitabine-albumin-based paclitaxel chemotherapy combined with SBRT in the treatment of newly diagnosed borderline resectable and locally advanced unresectable pancreatic cancer patients with sequential investigator selection (IC).

Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2

  • Status
    Not yet recruiting
  • Phase
    Phase 1
  • Condition
    Non-small Cell Lung Cancer
View Full Trial
INTERVENTION

Drug: Pembrolizumab, Other: Pemetrexed (Chemotherapy), Other: Nab-paclitaxel (Chemotherapy)

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

University of Rochester, Rochester, New York, United States

Brief Summary

The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2), which means you have limitations in carrying out certain activities or spend up to half of your day resting.

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

  • Status
    Active, not recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Non-Small Cell Lung Cancer
View Full Trial
INTERVENTION

Drug: Carboplatin, Drug: Nab-paclitaxel, Drug: MK-3475 (Phase I), Drug: MK-3475 (Phase II)

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

City of Hope, Duarte, California, United States

Brief Summary

This is a phase I/II study for previously untreated subjects with advanced NSCLC. The study will take place in two phases. First, a cohort of twelve participants will be enrolled in phase I part and will be treated with carboplatin, nab-paclitaxel and pembrolizumab. A cohort of twelve subjects will be evaluated for safety and tolerability after 2 cycles of therapy. All subjects who receive either nab-paclitaxel or pembrolizumab will be evaluable. If 33% of subjects or less have unacceptable toxicity in the first cohort or any subsequent cohort (if necessary), the study will proceed to the Phase II part. If more than 33% have unacceptable toxicity, 12 additional subjects will be enrolled in a second cohort, if necessary. If unacceptable toxicity is seen in more than 33% in Cohort 2, the study will end due to unacceptable toxicity of this drug combination. The phase II part of the study is a single arm study. All subjects will be treated with carboplatin, nab-paclitaxel, and pembrolizumab in 21-day cycles for up to 4 cycles. Mandatory pre-treatment tumor biopsies will be obtained prior to initiating treatment for all subjects (only if adequate archived samples are unavailable). Mandatory tumor biopsies will be obtained in the Phase II part of the study after 4 cycles of study treatment or at the time of progression, whichever comes first. For subjects without progression of disease after Cycle 4, pembrolizumab will continue every 3 weeks for up to 2 years or until unacceptable toxicity.

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer

  • Status
    Not yet recruiting
  • Phase
    Phase 2
  • Condition
    Gastric Cancer, GastroEsophageal Cancer
View Full Trial
INTERVENTION

Drug: Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Drug: Albumin-bound Paclitaxel

Eligibility
  • Ages: 18 to 70 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Tongji hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Brief Summary

This is a Multi-center, Open-label, Randomized Controlled,phase 2 clinical trail of Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor)Versus Albumin-bound Paclitaxel as Second-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

  • Status
    Recruiting
  • Phase
    Phase 2
  • Condition
    Non-small Cell Lung Cancer
View Full Trial
INTERVENTION

Drug: Carboplatin, Drug: Paclitaxel, Drug: Ramucirumab

Eligibility
  • Ages: 18 Years and older (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Brief Summary

The purpose of this study is to determine if the combination of the three anti-cancer drugs carboplatin, paclitaxel, and ramucirumab is helpful in shrinking tumors or delaying tumor growth in participants with non-small cell lung cancer. This study will also assess whether it is safe to combine these drugs.

Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer

  • Status
    Recruiting
  • Phase
    Phase 1 Phase 2
  • Condition
    Locally Advanced and Metastatic Pancreatic Cancer
View Full Trial
INTERVENTION

Drug: PD-L1/CTLA4 BsAb, Combination Product: GP, Combination Product: FOLFIRINOX

Eligibility
  • Ages: 18 to 80 Years (Adult, Older Adult)
  • Sexes: All
  • Accepts Healthy Volunteers: No
Locations

Changhai hospital, Shanghai, Shanghai, China

Brief Summary

To evaluate the efficacy of PD-L1/CTLA4 BsAb for the second line treatment and the combination with chemotherapy for the first line treatment in pancreatic cancer